AUSTIN, Texas, Feb. 27, 2017 /PRNewswire/ -- International Biophysics Corporation, a global medical device manufacturer based in Austin, Texas, today announced a 34% revenue growth in 2016 when compared to the previous year based upon a 53% increase in unit sales. This growth was fueled by its AffloVest® sales in the United States in addition to the expansion of its global sales of surgical product lines.
Said H. David Shockley, Jr., International Biophysics' CEO, "As we enter our 25th year in delivering high-quality, innovative medical devices to patients in underserved markets, we are seeing rapid growth in our market share in both respiratory and surgical devices. Based upon results to date, we are highly confident that 2017 will continue and even exceed this trend of increased sales growth across all of our product offerings."
AffloVest is the newest technology in High Frequency Chest Wall Oscillation (HFCWO) therapy that mobilizes lung secretions and helps clear airways which can help prevent chest infections for patients with Bronchiectasis and other chronic respiratory conditions. AffloVest is the first and only completely self-contained, battery operated, portable and fully mobile during use High Frequency Chest Wall Oscillation (HFCWO) device.
Added Mr. Shockley, "Through our sales and marketing efforts, we are building awareness for the AffloVest in the COPD patient population for Bronchiectasis. We are pleased to see robust returns on our investments in infrastructure by moving production of the AffloVest from overseas to the United States and in growing our sales team here."
International Biophysics will be exhibiting at the Medtrade conference in Las Vegas this week. The company will be showcasing its AffloVest to the Durable Medical Equipment (DME) providers at the conference.
For more information, please contact:
International Biophysics Corporation
2101 E. St. Elmo Road #275 | Austin, TX 78744
Or visit: www.biophysicscorp.com
SOURCE International Biophysics Corporation